Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    TopAbstracts in AIDS and HIV 03/15/2010 - (DGNews)
    A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults - (N Engl J Med)
    Ritonavir, Inhaled Fluticasone Interact to Create Cushing's Syndrome Symptoms: Presented at AAAAI - (DGDispatch)
    Nevirapine Can Be Resumed 1 Year After Childbirth in Mothers With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 03/01/2010 - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV
      Updated HIV Guidelines: What Do They Mean for the Initiation of ART?
      Preventing and Treating PCP and MAC: A Continuing Challenge in HIV/AIDS Care
      What Is Good Practice? HIV Care Beyond ART
      Human Papillomavirus-Related Anal Squamous Cell Dysplasia and Carcinoma in HIV Infection
      Common Drug Interactions in Patients Receiving Antiretroviral Therapy

      Webcasts/CME archive

       Recent cases - AIDS and HIV
        Vinblastine, Rituximab And HAART, Treatment Of An HIV -Positive Patient With Multicentric Castleman's Disease
        Measles Mimicking HIV Seroconversion Syndrome: A Case Report
        Germ Cell Tumor Concomitant with Acquired Immune Deficiency Syndrome
        Multicentric Castleman's Disease & HIV infection
        A Patient with Neck Pain and Fever

        Cases archive
          




        my personal edition > aids and hiv > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Growth Hormone Prodrug Reduces Visceral Fat by 15% in HIV Patients With Fat Accumulation Syndrome: Presented at CROI

        By Ed Susman

        LOS ANGELES, CA -- February 28, 2007 -- The investigative growth hormone-releasing factor analog TH9507 appears to help patients infected with HIV to decrease their visceral fat levels by 15%, researchers reported here at the 14th annual Conference on Retroviruses and Opportunistic Infections (CROI).

        "We had agreed in discussion with the Food and Drug Administration that an 8% reduction in visceral fat accumulation would be significant," said Steven Grinspoon, MD, associate professor of medicine, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States.

        "We were pleased to get this 15.2% reduction among patients with visceral fat accumulation in HIV-infected patients," Dr. Grinspoon said in a press briefing on February 26th. In contrast, placebo patients increased their visceral fat accumulation by 5%, he said. This difference reached statistical significance at the P <.0001 level.

        In the trial, 275 patients with HIV were assigned to receive TH9507 and 137 patients were treated with placebo. Both groups received daily subcutaneous injections for 26 weeks. Patients were mainly men with an average age of 48 years. All the patients had stable HIV viral loads.

        Dr. Grinspoon said the primary endpoint of the trial was the percentage of change in visceral abdominal fat as assessed by computer-assisted tomography. In all, 80% of subjects completed 26 weeks.

        Although the visceral fat level was decreased by TH9507, he said patients' overall weight remained unchanged. Basically, he said, the fat migrated from the visceral abdomen to other parts of the body, he said.

        Dr. Grinspoon said the patients treated with TH9507 also achieved a significant reduction in triglycerides -- a decrease of 0.6 mmol compared with a 0.1-mmol increase among patients on placebo (P <.0010). The favourable total cholesterol to high density lipoprotein cholesterol ratio also improved, decreasing by 0.3 in patients on TH9507 and increasing by 0.2 in placebo patients (P <.001). There was no difference in adverse events between the 2 groups.

        "TH9507 may represent a novel treatment strategy for HIV patients with central fat accumulation, including those with impaired glucose homeostasis," Dr. Grinspoon said.

        The study was supported by Theratechnologies, Inc, Montreal, Canada.


        [Presentation title: Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-Blind Placebo-Controlled Trial With 412 Randomized Patients. Abstract 45]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send